<DOC>
	<DOCNO>NCT01241292</DOCNO>
	<brief_summary>The purpose study assess safety tolerability Elotuzumab give combination Lenalidomide low-dose Dexamethasone subject relapse refractory multiple myeloma ( MM ) Japan .</brief_summary>
	<brief_title>Japanese Study BMS-901608 ( Elotuzumab ) Combination With Lenalidomide Low Dose Dexamethasone</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>For additional information , please contact BMS oncology clinical trial information service 8552160126 email MyCancerStudyConnect @ emergingmed.com . Please visit www.BMSStudyConnect.com information clinical trial participation . Received 1 4 prior line therapy Measureable disease Men woman childbearing potential ( WOCBP ) must use two acceptable method contraception Men must agree use latex condom second form birth control sexual contact WOCBP must agree donate semen study drug therapy Subjects must willing refrain blood donation study drug therapy Subjects nonsecretory oligosecretory lightchain myeloma active/prior plasma cell leukemia know /suspect POEMS syndrome Solitary bone solitary extramedullary plasmacytoma evidence plasma cell dyscrasia Unable take aspirin daily prophylactic anticoagulation therapy . Prior history inability tolerate weekly 40 mg dexamethasone History renal failure History clinical significant thrombosis , treatment thrombosis require</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>